🇺🇸 Maxigesic in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 13

Most-reported reactions

1. Hypothyroidism — 2 reports (15.38%)
2. Oedema Peripheral — 2 reports (15.38%)
3. Tachycardia — 2 reports (15.38%)
4. Abdominal Abscess — 1 report (7.69%)
5. Angioedema — 1 report (7.69%)
6. Asthenia — 1 report (7.69%)
7. Asthma — 1 report (7.69%)
8. Back Pain — 1 report (7.69%)
9. Cardiac Failure Congestive — 1 report (7.69%)
10. Cerebral Hypoperfusion — 1 report (7.69%)

Source database →

Frequently asked questions

Is Maxigesic approved in United States?

Maxigesic does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Maxigesic in United States?

Yonsei University is the originator. The local marketing authorisation holder may differ — check the official source linked above.